WiseGuyReports.com adds “Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022)” new report to its research database. The report spread across 141 pages with table and figures.
According to Researcher, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.
Complete Report Details Available at https://www.wiseguyreports.com/reports/456543/diabetic-retinopathy-treatment-global-market-outlook-2015 .
North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.
Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.
Inquire more about this report at https://www.wiseguyreports.com/enquiry/456543/diabetic-retinopathy-treatment-global-market-outlook-2015 .
Type of Treatments Covered:
- Intraocular Steroid Injection
- Anti-Vascular Endothelial Growth Factor (VEGF) drug
- Laser Surgery
Disease Type Covered:
- Proliferative Diabetic Retinopathy (PDR)
- Non-Proliferative Diabetic Retinopathy (NPDR): Moderate, Mild, Severe.
End Users Covered:
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Other End Users
This report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Major Points in Table of Content
1 Executive Summary
3 Market Trend Analysis
3.6 Application Analysis
3.7 Emerging Markets
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Diabetic Retinopathy Treatment Market, By Treatment type
5.2 Intraocular Steroid Injection
5.4 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.5 Laser Surgery
6 Global Diabetic Retinopathy Treatment Market, By Disease Type
6.2 Proliferative Diabetic Retinopathy (PDR)
6.3 Non-Proliferative Diabetic Retinopathy (NPDR)
7 Global Diabetic Retinopathy Treatment Market, By End User
7.2 Ophthalmic Clinics
7.3 Ambulatory Surgical Centers
7.5 Other End Users
8 Global Diabetic Retinopathy Treatment Market, By Geography
8.1 North America
8.3 Asia Pacific
8.4 Rest of the World
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.5 Other Key Strategies
10 Company Profiling
10.1 Regeneron Pharmaceuticals Inc.
10.4 Bayer Healthcare
10.5 Alimera Sciences
10.6 Actavis PLC
10.7 BCN Peptides
10.8 Novartis AG
10.9 Ampio Pharmaceuticals
10.10 Kowa Group
10.11 Sirnaomics Incorporation
10.12 Abbott Laboratories Ltd
10.13 Glycadia Pharmaceuticals
10.14 Alcon Laboratories Inc.
10.15 Parexel International Corp.
Order a Purchase Report Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=456543 .
P: +44 208 133 9349
M: +1 646 845 9349